Tirzepatide (CAS# 2023788-19-2), also known as LY3298176, is a synthetic 39-amino-acid linear peptide conjugated to a C20 fatty diacid moiety with the molecular formula C₂₂₅H₃₄₈N₄₈O₆₈ and a molecular weight of 4813.45 g/mol. Its molecular architecture is based on the endogenous glucose-dependent insulinotropic polypeptide (GIP) sequence, strategically modified to achieve balanced dual agonism at both GIP and GLP-1 receptors while conferring an extended half-life that enables once-weekly dosing. The C20 fatty diacid side chain, attached via a linker to the lysine residue at position 20, promotes albumin binding and extends the peptide’s circulatory half-life, a critical design feature for chronic metabolic disease management. Tirzepatide is a white to off-white lyophilized powder, freely soluble in water, with a specific rotation of −23.5° to −33.5° (calculated on the anhydrous and sodium-ion-free basis) and a pH of 6.0–9.0 in aqueous solution.
Tirzepatide is the first and only dual GIP and GLP-1 receptor agonist approved for human therapeutic use. It was approved by the FDA on May 13, 2022, under the brand name Mounjaro® for the treatment of adults with type 2 diabetes, and later under the brand name Zepbound® on November 8, 2023, for chronic weight management in adults with obesity or overweight with at least one weight-related condition. The European Commission approved tirzepatide on September 15, 2022. In December 2024, the FDA further expanded approval to include moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. In 2025, tirzepatide became the world’s highest-selling pharmaceutical, with total tirzepatide-related revenue reaching approximately $36.5 billion—the diabetes indication generating $22.965 billion (up 99% year-on-year) and the obesity indication reaching $13.542 billion (up 175%). Based on its chemical characteristics and unprecedented commercial significance, this article systematically analyzes the key properties, core application areas, global market structure, manufacturing landscape, regulatory framework, and future outlook of this strategically critical peptide API.
Core Application Fields and Demand
Market demand for tirzepatide (CAS# 2023788-19-2) is concentrated in three primary therapeutic sectors: type 2 diabetes mellitus (approximately 45–50% of API consumption), chronic weight management and obesity (approximately 35–40%), and emerging indications including obstructive sleep apnea and cardiovascular risk reduction (approximately 10–15%). The unprecedented commercial success of tirzepatide—surpassing all prior pharmaceutical sales records—has positioned its API as one of the most strategically important peptide drug substances in the global pharmaceutical supply chain.
In type 2 diabetes mellitus, tirzepatide is the first and only GIP/GLP-1 receptor agonist approved for glycemic control. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1, enhancing first- and second-phase insulin secretion and reducing glucagon levels in a glucose-dependent manner. The compound demonstrates therapeutic superiority in reducing blood glucose and body weight beyond several approved drugs such as semaglutide and dulaglutide in multiple head-to-head clinical trials. In China, following the successful inclusion of tirzepatide injection (brand name Mounjaro®) in the national medical insurance catalog, the monthly treatment cost for type 2 diabetes was reduced to as low as RMB 324.1, representing a decrease of over 80% from the initial monthly cost of approximately RMB 2,000. This dramatic price reduction is expected to significantly expand patient access and drive API volume growth, even as it compresses margins for generic manufacturers.
In chronic weight management and obesity, tirzepatide represents a paradigm shift in pharmacotherapy. The obesity indication (Zepbound®) generated $13.542 billion in 2025 revenue, growing 175% year-on-year. Tirzepatide’s dual mechanism—combining GIP receptor agonism, which activates a distinct population of GABA neurons in the area postrema, with GLP-1 receptor agonism—produces synergistic effects on body weight reduction that exceed those achievable with selective GLP-1 receptor agonists. With approximately 890 million adults living with obesity globally in 2022, the addressable market for tirzepatide API remains vast and largely underserved.
In obstructive sleep apnea (OSA) and emerging indications, the FDA approved Zepbound® in December 2024 as the first prescription medicine for moderate-to-severe OSA in adults with obesity, while the EMA determined that a separate OSA approval was not necessary as the indication is covered by the existing weight management approval. Ongoing clinical programs are investigating tirzepatide in cardiovascular risk reduction, metabolic dysfunction-associated steatohepatitis (MASH), and other metabolic conditions, which may further expand API demand.
Key Properties and Reactivity Profile
Tirzepatide (CAS# 2023788-19-2) is a complex synthetic peptide API whose value derives from its unique dual receptor pharmacology and extended half-life design.
Key physicochemical parameters include:
- Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
- Molecular Weight: 4813.45 g/mol (4813.5 ± 1.0 Da by MS)
- CAS Number: 2023788-19-2
- Synonyms: LY3298176; Mounjaro; Zepbound; tirzepatida; tirzepatidum
- Appearance: White or off-white powder; freely soluble in water
- Purity: ≥98.0% (HPLC); ≥99% available for high-purity grades
- Specific Rotation: −23.5° to −33.5° (anhydrous, sodium-ion-free basis)
- pH (aqueous solution): 6.0–9.0
- Water Content: ≤7.0%
- Acetic Acid: ≤0.5%
- Trifluoroacetic Acid: ≤0.5%
- Sodium Ion: ≤5.0%
- Assay of Peptide: ≥80.0%
- High Molecular Weight Substances: Single impurity ≤0.3%; Total impurities ≤0.8%
- Related Substances: Individual impurities ≤0.5%; Total impurities ≤2.0%
- Bacterial Endotoxin: ≤5 EU per mg
- Storage: Lyophilized powder at −20°C (long-term) or 2–8°C (short-term); protect from light and moisture
- GHS Classification: Not classified as hazardous under standard GHS criteria
The compound’s pharmacological activity is defined by its biased dual agonism mechanism. Molecular dynamics studies have revealed that conserved residues contribute similarly to binding at both GLP-1R and GIPR, while mutations in non-conserved residues affect binding affinity differentially—C-terminal mutations weaken binding affinity toward GLP-1R, while N-terminal mutations enhance affinity to GIPR, resulting in a biased binding mode. This structural insight, derived from cryo-EM and molecular dynamics simulations, has been instrumental in optimizing tirzepatide’s therapeutic profile and provides theoretical guidance for the design of future multi-target peptide agonists.
Manufacturing Landscape and Peptide Synthesis
The manufacturing of tirzepatide represents one of the most significant challenges in modern peptide chemistry. The 39-amino-acid sequence, combined with the C20 fatty diacid side chain, creates a molecule that is not efficiently accessible through conventional linear solid-phase peptide synthesis (SPPS) alone. The high-volume commercial demand—global API production reached approximately 1,159 kilograms in 2025—has catalyzed major innovations in convergent peptide synthesis strategies.
Convergent Hybrid SPPS/LPPS Strategy: To enable commercial-scale synthesis of tirzepatide, innovative four-fragment convergent hybrid SPPS/LPPS strategies have been pioneered, combining the individual strengths of solid-phase and liquid-phase peptide synthesis. This approach integrates flow chemistry for fragment condensation and nanofiltration for intermediate purification, ensuring high efficiency and scalability. The convergent approach allows for the simultaneous synthesis of high-purity peptide fragments, significantly reducing overall manufacturing time and increasing API throughput.
Native Chemical Ligation (NCL) and TFF-Assisted Synthesis: A two-fragment route leveraging Native Chemical Ligation (NCL) followed by tandem desulfurization has been established, achieving chemoselective coupling of unprotected peptide fragments in aqueous media without epimerization. Crucially, tangential flow filtration (TFF) is employed to effectively purify intermediates between ligation and desulfurization, circumventing solvent-intensive steps. This NCL/TFF combination offers a powerful, orthogonal, and greener path to tirzepatide, representing a meaningful innovation in synthetic peptide process chemistry.
Solid-State Property Optimization: Improving the solid-state properties of side-chain peptide building blocks for tirzepatide synthesis through complexation with metal cations (e.g., Mg-complexed lipidated side-chain building blocks) has been shown to enable comparable coupling performance relative to non-complexed derivatives, facilitating improved handling and storage of key intermediates.
Impurity Control Challenges: The manufacturing process faces significant challenges in controlling diketopiperazine (DKP) formation and associated double-amino-acid deletion impurities during linear SPPS of tirzepatide. Oxidation of methionine residues, deamidation-like variants, and truncation sequences represent additional critical quality attributes that must be controlled within stringent limits.
Major Market Participants
The global supply system for tirzepatide (CAS# 2023788-19-2) features a pattern of “originator dominance in drug product, specialized peptide CDMOs for API manufacturing, and a rapidly emerging Chinese peptide manufacturing ecosystem.”
Originator and Drug Product: Eli Lilly and Company is the drug sponsor for tirzepatide, coordinating global manufacturing and quality systems. Lilly has invested over $18 billion in global capacity expansion, including doubling its Lebanon, Indiana API facility investment to $9 billion, and a $3 billion commitment to China manufacturing operations for local production and supply.
In the global peptide CDMO segment, the top five players—Bachem (market leader with over 26% share in 2025), PolyPeptide Group, CordenPharma, Lonza, and WuXi STA (TIDES) —collectively held a market share of 80% in 2025. Samsung Biologics plays a contract manufacturing role in the broader injectable biopharma ecosystem. Thermo Fisher Scientific provides analytical and release testing services via its network suppliers.
In the Chinese API manufacturing segment, the landscape is rapidly evolving. As of the end of 2025, more than 20 Chinese enterprises had planned or established tirzepatide API production capacity. WuXi AppTec / WuXi STA (TIDES) serves as the largest supplier, providing 35% of Eli Lilly’s tirzepatide peptide API supply and 85% of active ingredient (API) supply. Its solid-phase peptide synthesis capacity was set to reach 100,000 liters by the end of 2025, with TIDES business revenue of RMB 7.84 billion in the first three quarters of 2025, up 121% year-on-year. Asymchem (凯莱英) has established 30,000 liters of solid-phase peptide synthesis capacity, with total capacity expected to reach 44,000 liters by year-end, positioning itself for high-difficulty long-chain modified peptide commercial production. Shengnuo Biopharmaceutical (圣诺生物) has commenced construction of a peptide API industrial production base project, with total planned annual capacity of 10 tons upon completion. Sinopep Pharmaceutical (诺泰生物) has achieved ton-level peptide capacity, with single-batch tirzepatide production exceeding 10 kg and planned additional capacity of 500 kg. Hanyu Pharmaceutical (翰宇药业) , through its Wuhan subsidiary, has obtained production licenses for 33 peptide APIs, with tirzepatide, semaglutide, and other products progressively entering production and supplying international markets. Taide Pharmaceutical (泰德医药) , a high-end peptide CDMO with dual China-US manufacturing bases, has established commercial delivery capabilities exceeding 30 kg per batch and over 500 kg annual capacity, directly serving European and American biotech clients.
XinChem is a reliable manufacturer and supplier of high-purity tirzepatide from China, offering the compound with stringent quality standards for use in pharmaceutical R&D, generic drug development, and clinical research applications. XinChem provides the compound as a white to off-white lyophilized powder with comprehensive quality documentation, batch-specific Certificates of Analysis (COA), customizable packaging, and globally compliant REACH, ISO 9001, and GMP-aligned manufacturing. The company emphasizes purity ≥98% (HPLC) with high-purity grades achieving ≥99%, and offers custom synthesis and contract manufacturing with flexible scaling from R&D to commercial quantities. Custom synthesis and contract manufacturing with flexible scaling from R&D to commercial quantities are available upon request.
Regional Market Dynamics
The global tirzepatide API market exhibits distinct regional characteristics, with production concentrated in North America and Europe (originator and top-tier CDMOs) and a rapidly expanding manufacturing ecosystem in Asia-Pacific, particularly China.
The global tirzepatide API market was valued at US
3,006millionin2025∗∗andisforecasttoreach∗∗US 15,301 million by 2032, growing at a CAGR of 18.4% during the review period. Global API production reached approximately 1,159 kilograms in 2025, with an average global market price of around US
2,520pergram∗∗[reference:32].Thebroadertirzepatidedrugmarketwasestimatedat∗∗US 16,461 million in 2024 and is forecast to reach US$ 69,808 million by 2031 at a CAGR of 19.8%.
North America remains the dominant market for tirzepatide drug product and high-purity API, with the largest share of global consumption. The United States hosts Eli Lilly’s manufacturing facilities, including the Lebanon, Indiana API site, as well as major peptide CDMO operations. The region’s competitive advantages include advanced peptide synthesis infrastructure, stringent regulatory compliance, and proximity to the originator’s quality systems.
Europe is a significant market for tirzepatide API manufacturing, with Bachem (Switzerland), PolyPeptide Group (Switzerland/Sweden), and CordenPharma (Germany) providing high-quality peptide API manufacturing services. The European Union’s approval of tirzepatide for type 2 diabetes and weight management, coupled with the EMA’s determination on OSA, supports steady demand for compliant API production.
The Asia-Pacific region is the fastest-growing market for tirzepatide API manufacturing, with China emerging as a major peptide production hub. China’s competitive advantages include lower production costs, established peptide synthesis infrastructure, and a growing ecosystem of CDMOs and API manufacturers. The concentration of more than 20 enterprises with tirzepatide API capacity in China, collectively planning hundreds of kilograms to ton-level production, reflects the region’s strategic focus on capturing GLP-1 API market share. However, regulatory and quality compliance for export to regulated markets remains a critical success factor.
Regulatory and Safety Considerations
As a complex synthetic peptide API and prescription pharmaceutical, tirzepatide (CAS# 2023788-19-2) is subject to stringent regulatory oversight in major global economies. Compliance with relevant regulations is essential for market access and trade.
Regulatory Approvals: Tirzepatide was approved by the FDA on May 13, 2022, for type 2 diabetes (Mounjaro®), by the European Commission on September 15, 2022, by Health Canada on November 2, 2023, and by the FDA on November 8, 2023, for chronic weight management (Zepbound®). In December 2024, the FDA approved Zepbound® for moderate-to-severe obstructive sleep apnea in adults with obesity, while the EMA determined that the existing weight management approval covers the OSA indication.
Quality Standards and Impurity Control: Tirzepatide API must comply with stringent specifications including purity ≥98.0% (HPLC), individual impurities ≤0.5%, total impurities ≤2.0%, high molecular weight substances ≤0.8%, sodium ion content ≤5.0%, water content ≤7.0%, and bacterial endotoxin ≤5 EU/mg. The compound requires full characterization by amino acid ratio analysis, mass spectrometry, and chiral purity assessment. Residual solvents must comply with ICH Q3C limits, and elemental impurities must meet ICH Q3D requirements.
Manufacturing Compliance: Tirzepatide API production requires GMP-compliant manufacturing facilities with validated processes for peptide synthesis, purification (including preparative HPLC and lyophilization), and quality control. The Drug Master File (DMF) filing is a critical regulatory step for API manufacturers seeking to supply regulated markets—for example, CPC Scientific’s tirzepatide API successfully secured US FDA DMF filing under DMF number 043979.
Storage and Stability: Tirzepatide lyophilized powder should be stored at −20°C for long-term storage or 2–8°C for short-term storage, protected from light and moisture. The compound is stable under recommended storage conditions, but reconstituted solutions should be used promptly or stored according to manufacturer specifications.
Transport Information: Tirzepatide API is not classified as hazardous material for DOT/IATA transport purposes. Proper packaging, labeling, and documentation are required for international shipping, including compliance with cold-chain requirements where applicable. The compound is typically shipped as a lyophilized powder at ambient or refrigerated temperature with appropriate moisture protection.
Future Outlook
The market outlook for tirzepatide API is exceptionally positive, supported by unprecedented commercial demand, expanding therapeutic indications, and major investments in peptide manufacturing capacity. The global tirzepatide API market is projected to grow from US
3,006millionin2025toUS 15,301 million by 2032, registering a CAGR of 18.4%.
Key growth drivers include:
- Unprecedented commercial demand and price-driven volume expansion: Tirzepatide became the world’s highest-selling pharmaceutical in 2025, with total revenue reaching approximately $36.5 billion. In China, the inclusion of tirzepatide in the national medical insurance catalog has reduced monthly treatment costs by over 80% to as low as RMB 324.1, which is expected to dramatically expand patient access and drive API volume growth despite margin compression. The U.S. government’s agreement to reduce GLP-1 drug prices to approximately $350 per month further supports global volume expansion.
- Expansion of therapeutic indications: Beyond type 2 diabetes and obesity, tirzepatide is being investigated in cardiovascular risk reduction, MASH, heart failure with preserved ejection fraction, and other metabolic conditions. The FDA approval for OSA represents the first of several potential label expansions that will broaden the API addressable market.
- Massive capacity investments by originator and CDMOs: Eli Lilly has committed over $18 billion to global capacity expansion, including $3 billion for China manufacturing operations. Top-tier CDMOs (Bachem, PolyPeptide Group, CordenPharma, Lonza, WuXi STA) collectively held 80% market share in 2025 and continue to expand capacity to meet surging demand.
- Emergence of generic and biosimilar competition: With core patents for tirzepatide approaching expiration, more than 20 Chinese enterprises have planned or established tirzepatide API production capacity, positioning themselves to supply the generic market. This competitive dynamic will drive API price reductions and further volume expansion.
- Technological advances in peptide synthesis: Convergent hybrid SPPS/LPPS strategies, NCL/TFF-assisted synthesis, and metal-complexed building blocks are reducing manufacturing costs and increasing API throughput, making tirzepatide more accessible for global patients.
Challenges and considerations:
- Manufacturing complexity and capacity constraints: The 39-amino-acid sequence with C20 fatty diacid modification requires sophisticated convergent synthesis strategies. The complexity of synthetic peptide manufacturing, along with stringent purification and quality consistency requirements, creates significant barriers to rapid capacity expansion, resulting in short-term supply constraints.
- Impurity control: DKP formation, double-amino-acid deletion impurities, oxidation variants, and deamidation products require rigorous process control and advanced analytical methods to meet regulatory specifications.
- Price erosion: The dramatic price reductions in China and the U.S. government’s pricing agreement signal a long-term trend of price compression that will pressure API margins, particularly for generic manufacturers.
- Regulatory compliance: Increasingly stringent quality and sourcing compliance requirements reinforce the importance of compliant production capacity, shifting competition toward integrated capabilities in efficiency, cost control, and supply chain resilience.
- Supply chain concentration: The concentration of high-quality peptide API manufacturing in a limited number of CDMOs creates potential supply chain vulnerabilities that may concern pharmaceutical companies seeking diversification.
To succeed in this evolving market landscape, suppliers must focus on product quality (particularly purity, impurity profile, and batch-to-batch consistency), supply chain reliability, regulatory compliance, and manufacturing cost optimization. Companies that can offer high-purity products with comprehensive Certificates of Analysis (COA), DMF support, flexible packaging options, and technical support for pharmaceutical development will be well-positioned to capture growing demand.
Shanghai XinChem Co., Ltd. (XinChem)
As a world-leading supplier of organic chemicals and pharmaceutical intermediates, Shanghai XinChem Co., Ltd. (XinChem) is dedicated to meeting the innovative needs of the pharmaceutical, biotechnology, and metabolic disease therapeutic industries. Leveraging extensive experience and advanced manufacturing capabilities, XinChem provides high-quality Tirzepatide (CAS# 2023788-19-2) to customers worldwide. As a trusted manufacturer and supplier based in China, XinChem combines competitive pricing, reliable supply, and exceptional service to establish itself as a preferred partner for pharmaceutical companies, generic drug developers, and research institutions seeking this first-in-class GIP/GLP-1 dual receptor agonist peptide API.
1. Technical Advantages
Advanced Peptide Synthesis and Purification Processes
XinChem utilizes state-of-the-art manufacturing facilities and rigorous quality control measures to ensure the purity, consistency, and safety of its tirzepatide products. The production process incorporates advanced peptide synthesis technologies—including solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), and hybrid synthesis strategies—enabling the delivery of products with purity ≥98.0% (HPLC) and ≥99% for high-purity grades to meet diverse application requirements. Strict process control ensures consistent product quality, minimal impurities (including DKP, truncation, and oxidation variants), and batch-to-batch reproducibility, providing customers with reliable performance in pharmaceutical development and generic drug manufacturing.
Full-Chain Quality Control
The production process strictly adheres to international quality standards, with comprehensive quality control covering raw material sourcing, in-process monitoring, and finished product testing. Each batch is accompanied by a detailed Certificate of Analysis (COA) documenting physical and chemical properties, purity data (HPLC), specific rotation, water content, acetic acid content, trifluoroacetic acid content, sodium ion content, residual solvents, high molecular weight substances, related substances, and bacterial endotoxin. XinChem offers batch-specific COA, customizable packaging, and globally compliant REACH, ISO 9001, and GMP-aligned manufacturing.
2. Product Advantages
High Purity and Consistent Quality
XinChem offers tirzepatide with purity ≥98.0% (HPLC) and ≥99% available, ensuring optimal performance in pharmaceutical R&D, generic drug development, and clinical research applications. The product’s high purity and consistent quality minimize the risk of unwanted side reactions and impurities, making it suitable for demanding applications in metabolic disease therapeutics. The compound is supplied as a white to off-white lyophilized powder, freely soluble in water, with a specific rotation of −23.5° to −33.5° and a pH of 6.0–9.0 in aqueous solution.
Comprehensive Specifications
Key specifications include:
- Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
- Molecular Weight: 4813.45 g/mol (4813.5 ± 1.0 Da by MS)
- CAS Number: 2023788-19-2
- Synonyms: LY3298176; Mounjaro; Zepbound; tirzepatida; tirzepatidum
- Appearance: White or off-white powder; freely soluble in water
- Purity: ≥98.0% (HPLC) / ≥99% available
- Specific Rotation: −23.5° to −33.5° (anhydrous, sodium-ion-free basis)
- pH (aqueous solution): 6.0–9.0
- Water Content: ≤7.0%
- Acetic Acid: ≤0.5%
- Trifluoroacetic Acid: ≤0.5%
- Sodium Ion: ≤5.0%
- Assay of Peptide: ≥80.0%
- High Molecular Weight Substances: Single impurity ≤0.3%; Total impurities ≤0.8%
- Related Substances: Individual impurities ≤0.5%; Total impurities ≤2.0%
- Bacterial Endotoxin: ≤5 EU per mg
- Storage: −20°C (long-term) or 2–8°C (short-term), protect from light and moisture
Flexible Packaging Solutions
XinChem provides a range of packaging options to accommodate diverse customer needs, from laboratory-scale quantities (10 mg, 50 mg, 100 mg) to industrial-scale packaging (1 g, 5 g, 10 g, 100 g, 500 g, 1 kg) and bulk shipments. Customized packaging solutions are available upon request, ensuring safe handling, storage, and transportation with appropriate protection from light and moisture.
3. Application Fields
As a first-in-class GIP/GLP-1 dual receptor agonist peptide, Tirzepatide (CAS# 2023788-19-2) exhibits wide application value across multiple therapeutic areas:
Type 2 Diabetes Mellitus:
- First and only GIP/GLP-1 receptor agonist approved for glycemic control
- Enhances first- and second-phase insulin secretion and reduces glucagon levels in a glucose-dependent manner
- Demonstrates therapeutic superiority in reducing blood glucose beyond semaglutide and dulaglutide in head-to-head trials
- Reduces monthly treatment costs to as low as RMB 324.1 through medical insurance inclusion in China
Chronic Weight Management and Obesity:
- FDA-approved Zepbound® for chronic weight management in adults with obesity or overweight
- Dual mechanism produces synergistic effects on body weight reduction exceeding selective GLP-1 receptor agonists
- Addressable market of approximately 890 million adults living with obesity globally
Obstructive Sleep Apnea and Emerging Indications:
- FDA-approved as first prescription medicine for moderate-to-severe OSA in adults with obesity
- Ongoing clinical programs in cardiovascular risk reduction, MASH, heart failure, and other metabolic conditions
- Expanding therapeutic applications support growing API demand
4. Service Support
Technical Expertise and Customized Solutions
XinChem’s team of experienced peptide chemists and pharmaceutical scientists provides full technical support throughout the customer journey—from product selection and specification development to application guidance and troubleshooting. Whether customers require optimization of peptide synthesis routes, guidance on impurity control strategies, or assistance with regulatory documentation including DMF support, XinChem’s technical experts are ready to help. Custom synthesis and contract manufacturing with flexible scaling from R&D to commercial quantities are available upon request.
Global Logistics and Reliable Supply
With established supply chains serving markets across Europe, North America, Asia-Pacific, and beyond, XinChem ensures timely delivery and consistent product availability. The company’s logistics team manages all aspects of international shipping, including compliance with cold-chain requirements, customs clearance, and documentation, with appropriate temperature control and moisture protection for product stability.
Regulatory Support
XinChem provides comprehensive documentation to support regulatory compliance, including Safety Data Sheets (SDS), Certificates of Analysis (COA), and other required certificates. The company stays current with evolving regulatory requirements in major markets, including FDA, EMA, and other regional regulations, helping customers navigate the complexities of global pharmaceutical trade and DMF filing requirements.
5. Reasons to Choose XinChem
- Professionalism: Extensive experience and deep expertise in peptide API synthesis and supply.
- Quality: Rigorous quality control, high purity (≥98% to ≥99%), and adherence to international standards.
- Reliability: Stable supply, competitive pricing, and timely delivery.
- Flexibility: Customized solutions to meet diverse customer needs, including custom synthesis, DMF support, and packaging.
- Service: Responsive technical support and comprehensive documentation including batch-specific COA.
Contact us today to start your partnership with XinChem!
Website: www.xinchem.com
Email: sales1@xinchem.com
WhatsApp: +86 18049800532
Post time: Oct-04-2026